Methods of Treating Ovarian Cancer
The present invention provides methods of administering a PARP inhibitor to a cancer patient.
1 .- 90 . (canceled)
91 . A method of treating a patient diagnosed with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, the method comprising administering to said patient niraparib tosylate monohydrate, wherein the patient is HRD negative and wherein the patient has shown a partial or complete response to platinum-based chemotherapy.
92 . The method of claim 91 , wherein the niraparib tosylate monohydrate is administered in a single daily dose.
93 . The method of claim 91 , wherein the niraparib tosylate monohydrate is administered orally.
94 . The method of claim 93 , wherein the niraparib tosylate monohydrate is administered in the form of one or more unit dosage forms equivalent to about 100 mg of niraparib free base.
95 . The method of claim 94 , wherein the one or more unit dosage forms are capsules.
96 . The method of claim 91 , wherein the niraparib tosylate monohydrate is administered in a dose equivalent to about 200 mg or about 300 mg of niraparib free base.
97 . The method of claim 91 , wherein the administration of niraparib tosylate monohydrate is commenced within 8 weeks of the end of the last cycle of platinum-based chemotherapy.
98 . The method of claim 91 , wherein the patient is diagnosed with recurrent epithelial ovarian cancer.
99 . The method of claim 91 , wherein the patient is diagnosed with recurrent fallopian tube cancer.
100 . The method of claim 91 , wherein the patient is diagnosed with recurrent primary peritoneal cancer.
101 . The method of claim 91 , wherein the treatment is maintenance treatment.
102 . The method of claim 91 , wherein the patient is an adult.
103 . A method of treating a patient diagnosed with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, the method consisting of administering to said patient niraparib tosylate monohydrate, wherein the patient is HRD negative and wherein the patient has shown a partial or complete response to platinum-based chemotherapy.
104 . The method of claim 103 , wherein the niraparib tosylate monohydrate is administered in a single daily dose.
105 . The method of claim 103 , wherein the niraparib tosylate monohydrate is administered orally.
106 . The method of claim 103 , wherein the niraparib tosylate monohydrate is administered in a dose equivalent to about 200 mg or about 300 mg of niraparib free base.
107 . The method of claim 103 , wherein the administration of niraparib tosylate monohydrate is commenced within 8 weeks of the end of the last cycle of platinum-based chemotherapy.
108 . The method of claim 103 , wherein the patient is diagnosed with recurrent epithelial ovarian cancer.
109 . The method of claim 103 , wherein the patient is diagnosed with recurrent fallopian tube cancer.
110 . The method of claim 103 , wherein the patient is diagnosed with recurrent primary peritoneal cancer.
111 . A method of treating a patient diagnosed with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, the method comprising administering daily to said patient an oral dose of niraparib tosylate monohydrate equivalent to about 200 mg or about 300 mg of niraparib free base, wherein the patient is HRD negative and wherein the patient has shown a partial or complete response to platinum-based chemotherapy.
112 . The method of claim 111 , wherein the administration of niraparib tosylate monohydrate is commenced within 8 weeks of the end of the last cycle of platinum-based chemotherapy.
113 . The method of claim 111 , wherein the patient is diagnosed with recurrent epithelial ovarian cancer.
114 . The method of claim 111 , wherein the patient is diagnosed with recurrent fallopian tube cancer.
115 . The method of claim 111 , wherein the patient is diagnosed with recurrent primary peritoneal cancer.
116 . A method of treating a patient diagnosed with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, the method consisting of administering daily to said patient an oral dose of niraparib tosylate monohydrate equivalent to about 200 mg or about 300 mg of niraparib free base, wherein the patient is HRD negative and wherein the patient has shown a partial or complete response to platinum-based chemotherapy.
117 . The method of claim 116 , wherein the administration of niraparib tosylate monohydrate is commenced within 8 weeks of the end of the last cycle of platinum-based chemotherapy.
118 . The method of claim 116 , wherein the patient is diagnosed with recurrent epithelial ovarian cancer.
119 . The method of claim 116 , wherein the patient is diagnosed with recurrent fallopian tube cancer.
120 . The method of claim 116 , wherein the patient is diagnosed with recurrent primary peritoneal cancer.